Upcoming Events
Recent courses
This session will inform HCPs on the tirzepatide molecule, the SURMOUNT global trial program for the treatment of obesity and overweight, and the safety and efficacy data disclosure for SURMOUNT-3
|
This session will include a discussion of how to diagnose and manage lipedema patients who also have obesity in conjunction with a plastic surgeon for the treatment of the disease to optimize outco
|
The patient with inflammatory bowel disease (IBD), either Crohn's disease or ulcerative colitis, faces specific challenges in the management of obesity.
|
Pages
The material presented by the Obesity Medicine Association (OMA) is for educational purposes only. Opinions expressed do not necessarily reflect those of OMA. The material is not intended to represent the only or necessarily best method or procedure appropriate for the medical situations discussed. Instead, it is intended to present an approach, view, statement, or opinion of the faculty that may be helpful to others who face similar situations. The individual is responsible for becoming familiar with laws and prescribing limitations within his or her own state before practicing various therapies. OMA also presents a forum for its members to be exposed to various products and services. It is the responsibility of each attendee or member to do due diligence, including reviewing literature, lectures, and background information.
OMA disclaims any and all liability for injury or other damages resulting to any individual viewing pages on obesitymedicine.org or academy.obesitymedicine.org and for all claims that may arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by physician or any other person.